Shortly after a Phase III trial failed to confirm Amylyx Pharmaceuticals, Inc.’s Relyvrio benefit in amyotrophic lateral sclerosis (ALS), Seelos Therapeutics, Inc. has revealed that its investigational drug SLS-005 did not meet the primary endpoint in a mid- and late-stage basket study, but showed an efficacy signal in patients who had not taken Relyvrio.
Seelos announced topline results from the Phase II/III HEALEY ALS Platform trial for SLS-005 (trehalose I.V
Key Takeaways
-
Seelos said the SLS-005 cohort in HEALEY ALS was overall unsuccessful, but showed an efficacy signal in the subgroup of patients not receiving Amylyx’s Relyvrio.
-
The company’s CEO said the company will meet with the FDA, though it anticipates conducting a Phase III trial of the drug, aiming for a “conservative route
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?